BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LYL273 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LYL273\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05319314-10895@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:LYL273: Phase 1/2 readout est. (NCT05319314)
DESCRIPTION:LYL273\, phase 1/2.\nStudy: LYL273 for Patients With Relapsed o
 r Refractory mCRC\nEstimated primary completion: June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lyl273#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05319314
URL:https://assetmemo.bio/drug/lyl273#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
